Vaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average Price Target from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten analysts that are covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $136.50.

Several equities analysts have issued reports on the stock. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Bank of America decreased their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Needham & Company LLC reissued a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded up $0.43 on Friday, hitting $31.59. The company's stock had a trading volume of 2,133,837 shares, compared to its average volume of 1,312,725. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of -6.87 and a beta of 1.27. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $121.06. The firm has a fifty day moving average price of $45.81 and a 200-day moving average price of $73.63.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the business earned ($0.85) earnings per share. As a group, analysts forecast that Vaxcyte will post -4.21 EPS for the current year.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at $9,180,820.35. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $28,000. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI purchased a new stake in shares of Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. lifted its stake in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after acquiring an additional 371 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.